An observational study in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Hypercholerolemia and Hypertension, sponsored by Zuyderland Medisch Centrum. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Zuyderland Medisch Centrum · Observational
Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate in intensity or incomplete in application. As a result, important opportunities to prevent serious outcomes are missed.
The aim of this project is to investigate whether rapid, guideline-based treatment following myocardial infarction leads to improved patient outcomes. The study protocol is based on current clinical guidelines and targets key domains including diabetes, hypertension, and hypercholesterolemia. Outcomes of patients treated according to the study protocol will be compared to those receiving standard care. Primary endpoints include major adverse cardiac- and cerebrovascular events within a 24-month follow-up period.
The investigators hypothesize that rapid, guideline-based intervention will result in improved risk factor management, leading to a reduction in cardiovascular events and mortality. For patients, this may translate into improved health, quality of life and life expectancy. This project aims to deliver a practical protocol for effective secondary prevention in clinical practice, which is expected to reduce healthcare utilization in the long term. With this initiative, the investigators seek to take a significant step toward improving post-myocardial infarction care and contributing to sustainable cardiovascular healthcare.
1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
This study's planned enrollment of 1,215 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Zuyderland Medisch Centrum is the lead sponsor of 64 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of patients, hospitalised in Zuyderland, who underwent a percutaneous coronary intervention due to an acute coronary syndrome (unstable angina (UA), ST-elevation myocardial infarction (STEMI), or non ST-elevation myocardial infarction (non-STEMI)).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the intervention group, patients will be treated according to a rapid ESC-guideline-based protocol. This approach will target: 1\. Optimal pharmacological treatment, including: * Lipid-lowering * Antihypertensive * Diabetic, such sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) * Glucagon-like peptide-1 agonists (GLP-1 agonists)
MACCE within 2 years after the ACS and PCI
The occurrence of major adverse cardiac- and cerebrovascular events (MACCE) defined as the composite of all cause death, myocardial infarction, (ischemic or hemorrhagic) CVA, and ischemia-driven revascularization at 24 months.
Time frame: From enrollment to end of 2 year follow-up
30 days endpoints checklist
Prevelance of the following endpoints with 30 days after discharge: * Death due to any cause * Cardiovascular mortality * Reacurent acute coronary syndrom * Ischemia-driven revascularization * Ischemic CVA * Haemorrhagic CVA * Uplanned cardiovascular hospital readmission * New onset of diabetes mellitus type 2 * New onset of peripheral arterial disease * Sustained decline of eGFR of 50% for more than 3 months based on eGFR lab value Measures will be defined as either present or absent and collected via medical record.
Time frame: From discharge till 30 days after discharge
Quality of life survey at 30 days
Patients recieve a quality of life survey at 30 days after discharge. This is done with a SF-36 questionnaire
Time frame: 30 days after discharge
1 year endpoints checklist
Prevelance of the following endpoints 1 year after discharge: * Death due to any cause * Cardiovascular mortality * Reacurent acute coronary syndrom * Ischemia-driven revascularization * Ischemic CVA * Haemorrhagic CVA * Uplanned cardiovascular hospital readmission * New onset of diabetes mellitus type 2 * New onset of peripheral arterial disease * Sustained decline of eGFR of 50% for more than 3 months Measures will be defined as either present or absent and collected via medical record.
Time frame: Between 30 days and 1 year after discharge
Quality of life survey at 1year
Patients recieve a quality of life survey at 1year after discharge. This is done with a SF-36 questionnaire
Time frame: 1 year after discharge
2 year endpoints checklist
Prevelance of the following endpoints 2 years after discharge: * Death due to any cause * Cardiovascular mortality * Reacurent acute coronary syndrom * Ischemia-driven revascularization * Ischemic CVA * Haemorrhagic CVA * Uplanned cardiovascular hospital readmission * New onset of diabetes mellitus type 2 * New onset of peripheral arterial disease * Sustained decline of eGFR of 50% for more than 3 months Measures will be defined as either present or absent and collected via medical record.
Time frame: Between 1 en 2 years after discharge
Quality of life survey at 2 years
Patients recieve a quality of life survey at 2 years after discharge. This is done with a SF-36 questionnaire
Time frame: 2 years after discharge
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zuyderland Medisch Centrum